{"id":646,"date":"2026-10-26T11:13:29","date_gmt":"2026-10-26T11:13:29","guid":{"rendered":"https:\/\/snap-trove.co.za\/?p=646"},"modified":"2026-10-26T11:13:29","modified_gmt":"2026-10-26T11:13:29","slug":"aging-is-becoming-a-drug-target","status":"publish","type":"post","link":"https:\/\/snap-trove.co.za\/index.php\/2026\/10\/26\/aging-is-becoming-a-drug-target\/","title":{"rendered":"Aging Is Becoming a Drug Target. The Question Is Whether It\u2019s a Disease"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">For most of modern medicine, aging has been treated as an inevitable backdrop to disease. Doctors treat cancer, diabetes, cardiovascular disease, and dementia, while the biological process that makes all of them more likely remains largely outside the boundaries of conventional treatment. That division is beginning to break down.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A growing pipeline of longevity drugs aims to intervene in aging itself, extending the years people spend healthy rather than targeting individual diseases one at a time. The scientific ambition is enormous. So are the implications for how medicine defines illness, approves treatments, and makes money.<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-647\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-a-drug-problem-now-300x202.jpg\" alt=\"aging is a drug problem now\" width=\"300\" height=\"202\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-a-drug-problem-now-300x202.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-a-drug-problem-now-768x518.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-a-drug-problem-now.jpg 804w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">The Drugs Already on the Table<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-650\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/rapamicyn-300x202.jpg\" alt=\"\" width=\"300\" height=\"202\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/rapamicyn-300x202.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/rapamicyn-768x518.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/rapamicyn.jpg 804w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">Rapamycin, a drug originally developed to prevent organ transplant rejection, has become one of the most closely studied candidates for extending lifespan. In a landmark mouse experiment, researchers found that administering rapamycin late in life increased maximum lifespan by approximately 9% in males and 14% in females. The drug inhibits mTOR, a cellular pathway involved in growth, metabolism, and the regulation of aging.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The significance is that the intervention worked even when treatment began relatively late in life. Rather than requiring a lifetime of preventive measures, it suggested that some mechanisms underlying aging remain modifiable after the damage has accumulated.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Metformin, a widely prescribed diabetes medication, is at the centre of another major effort: the Targeting Aging with Metformin (TAME) trial. Its objective is to investigate whether the drug can delay the onset of multiple age-related conditions. The project has spent years pursuing a regulatory breakthrough that could reshape longevity research: FDA acceptance of a composite endpoint that measures outcomes across several diseases associated with aging.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That precedent matters enormously. Aging itself has historically lacked recognition as a disease indication for drug approval. A framework for evaluating interventions against multiple age-related outcomes could give researchers a path toward testing treatments designed to improve the aging process as a whole.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The pharmaceutical industry is also approaching longevity through GLP-1 receptor agonists such as semaglutide. Already transforming the treatment of obesity and diabetes, these drugs are now attracting attention for their potential effects on biological aging. Company-reported analyses have identified differences in molecular aging clocks equivalent to roughly two or three years, while an epigenetic sub-study associated with Eli Lilly&#8217;s incretin-based treatment found that all 15 clocks examined indicated younger biological ages than chronological time would predict.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">These measurements are early signals, but they illustrate the direction of research: treatments developed for one purpose are being investigated for their ability to influence the underlying biology of aging.<\/span><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">The Race to Turn Back the Clock<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-651\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/xprize-300x202.jpg\" alt=\"\" width=\"300\" height=\"202\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/xprize-300x202.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/xprize-768x518.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/xprize.jpg 804w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">The ambitions become even more striking in the XPRIZE Healthspan competition, which challenges teams to restore muscle strength, cognitive function, and immune performance in adults aged 50 to 90. The target is an improvement equivalent to at least 10 years of biological function, with an aspirational goal of 20 years, achieved within a treatment period of one year or less.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">One participating team is pursuing engineered super exosomes designed to target senescent cells. These cells have stopped dividing but remain metabolically active, releasing inflammatory signals that can damage surrounding tissue and contribute to age-related dysfunction. By targeting cellular processes associated with aging, the approach aims to restore function across multiple systems simultaneously.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The team estimates that its preclinical results correspond to more than 15 healthy human years. Such projections illustrate the scale of the competition&#8217;s ambitions: researchers are attempting to demonstrate measurable rejuvenation, rather than simply slowing the rate of decline.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">That distinction could determine the future of longevity medicine. A treatment that delays deterioration may offer incremental benefits. One that restores lost function could fundamentally change what clinicians and patients expect from later life.<\/span><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">The Regulatory Revolution<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-648\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-treatable-300x202.jpg\" alt=\"\" width=\"300\" height=\"202\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-treatable-300x202.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-treatable-768x518.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/aging-is-treatable.jpg 804w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">The central obstacle to longevity medicine has always been partly administrative. Regulators need defined indications, measurable outcomes, and evidence that a treatment produces clinically meaningful benefits. Aging, meanwhile, unfolds across decades and affects nearly every organ system.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Recognizing aging as a treatable target would create a new category of medicine. Pharmaceutical companies could develop therapies intended to postpone several diseases simultaneously, potentially changing how clinical trials are designed and how treatments are prescribed. Healthcare systems could begin evaluating interventions according to the healthy years they preserve, rather than waiting for individual diseases to emerge.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The commercial incentives are equally powerful. A drug that meaningfully delays age-related decline could have a market spanning a substantial portion of the adult population. The existing longevity pipeline already demonstrates how established medications can acquire new significance when researchers reinterpret their effects through the biology of aging.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This is why the TAME effort carries consequences beyond metformin. Establishing an accepted way to measure and treat age-related deterioration could unlock an entire field of drug development.<\/span><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">What Does It Mean to Treat Aging?<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-649\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/is-aging-a-desease-300x202.jpg\" alt=\"\" width=\"300\" height=\"202\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/is-aging-a-desease-300x202.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/is-aging-a-desease-768x518.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/10\/is-aging-a-desease.jpg 804w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">The ultimate question is whether aging should be classified as a disease, a collection of diseases, or a biological process that medicine has simply learned to tolerate.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The distinction has practical consequences. If aging becomes a recognized therapeutic target, interventions could be developed and prescribed before patients become seriously ill. Prevention could move upstream, addressing the shared biological mechanisms behind multiple conditions instead of treating each one after symptoms appear.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Even modest extensions of healthy life could have profound effects when applied across millions of people. A few additional years of mobility, independence, and cognitive function would change the experience of old age for individuals and reshape the demands placed on healthcare systems.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The emerging longevity industry is built around a radical proposition: the deterioration associated with aging may be sufficiently modifiable to become a central objective of medicine.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The first generation of treatments may produce incremental gains. The regulatory framework, however, could outlast any individual drug. Once aging becomes something medicine can formally measure and target, the boundary between treating disease and treating the passage of time begins to shift.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The question is no longer simply how long humans can live. It is whether medicine will eventually regard the biological process of getting older as one of its primary therapeutic targets \u2014 and how much of human life could change if it does.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>For most of modern medicine, aging has been treated as an inevitable backdrop to disease. Doctors treat cancer, diabetes, cardiovascular disease, and dementia, while the biological process that makes all&#8230;<\/p>\n","protected":false},"author":1,"featured_media":647,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,1,6],"tags":[],"class_list":["post-646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-exclusives","category-hot-news","category-science"],"_links":{"self":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts\/646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/comments?post=646"}],"version-history":[{"count":1,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts\/646\/revisions"}],"predecessor-version":[{"id":652,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts\/646\/revisions\/652"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/media\/647"}],"wp:attachment":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/media?parent=646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/categories?post=646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/tags?post=646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}